Compare WFCF & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFCF | KLRS |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.5M | 46.0M |
| IPO Year | 2011 | N/A |
| Metric | WFCF | KLRS |
|---|---|---|
| Price | $11.30 | $8.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $20.67 |
| AVG Volume (30 Days) | 1.9K | ★ 67.7K |
| Earning Date | 02-19-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.82 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $25,512,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.26 | $2.14 |
| 52 Week High | $13.78 | $12.90 |
| Indicator | WFCF | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.05 | 42.21 |
| Support Level | $11.15 | $8.75 |
| Resistance Level | $11.30 | $9.48 |
| Average True Range (ATR) | 0.08 | 0.65 |
| MACD | 0.05 | -0.18 |
| Stochastic Oscillator | 49.03 | 4.50 |
Where Food Comes From Inc is a third-party food verification company. It offers food production audits and uses verification processes to ensure that claims made by food producers and processors are accurate. The company supports farmers, ranchers, vineyards, wineries, processors, retailers, distributors, trade associations, and restaurants with a wide variety of value-added services provided through its family of verifiers, including International Certification Services, Validus Verification Services, and others. The company operates in two segments that are verification and certification and Software Sales and Related Consulting. It generates the majority of its revenue from verification and certification.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.